re . potential valuationsInsitutional investors usually step in above 2.00 per share on tsx listed companies, with that analylst coverage usually follows. To get a proper potential valuation, what is the potential annual revenue and from that the potential annual EBITA, usually stocks trade at a multipile to EBITA. What is the average multipile for the biotech field to EBITA. For example if a company generates 100 million a year in EBITA in some industries they will get a 12x multipile this would give a company a 1.2 billion dollar market cap. It would be interesting to determine what MBX potential is based on potential EBITA models as this may be how alot of analysts and insitutions determine potential values for companies.